3 news items
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
TAK
18 Jun 24
or stopping the infusion. Treatment will depend on the nature and severity of the adverse event. Patients should be reminded to report chronic
HEALWELL AI's Pentavere Announces Partnership with Takeda to Support Rare Disease Real-World Evidence Analysis for Patients living with Hereditary Angioedema
TAK
6 Jun 24
, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
TAK
27 Mar 24
tract3. While inflammation is the body's natural reaction to irritation or injury, in patients with IBD, it is thought that the body's own
- Prev
- 1
- Next